Epirubicin trials for Breast cancer

All Epirubicin trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Epirubicin for Breast cancer

• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  NCT06966700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 325 locations
• A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
  NCT07441460 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study for the Adjuvant Treatment of Breast Cancer
  NCT05420467 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 1 location
• A Study for the Neoadjuvant Treatment of Breast Cancer
  NCT05420454 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 1 location
• EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
  NCT05883852 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
  NCT04576143 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• MicroRNA Profiles in Triple Negative Breast Cancer
  NCT04771871 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations
• Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
  NCT07016399 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
  NCT06121570 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
  NCT06860529 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
  NCT05981014 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
  NCT05447702 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
  NCT05901428 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
  NCT06389006 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
  NCT05900206 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
  NCT06291064 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations
• Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
  NCT05978648 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Epirubicin for Breast cancer?

18 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.